Owkin

Owkin is a French health-tech company founded in 2016 by clinical oncologist Thomas Clozel and machine-learning researcher Gilles Wainrib, headquartered in Paris with additional offices in New York, London and Geneva. It was created to speed up biopharmaceutical research, where identifying the right patients, biomarkers and drug targets from fragmented clinical and biological data is slow and costly.

Its main product, K Pro, is an AI agent that connects research and care by analyzing multimodal patient data drawn from a hospital partner network, combined with wet-lab validation from Owkin’s own biology teams. The system supports hypothesis generation, biomarker discovery and target identification for drug development. Customers are pharmaceutical and biotech companies; Owkin has disclosed a licensing collaboration with Boehringer Ingelheim.

1. K Pro AI agent: generates research hypotheses from multimodal patient data.

2. Biomarker discovery: identifies patterns linked to disease outcomes and drug response.

3. Hospital data network: draws on real-world clinical data from partner medical centers.

4. Wet-lab validation: confirms computational findings through in-house biology teams.

5. Pharma collaboration: supports drug target identification for biopharma partners.

6. Licensing deals: active collaboration disclosed with Boehringer Ingelheim.